亚宝药业：前三季度净利润同比下降8.44%

Core Viewpoint - The financial performance of Yabao Pharmaceutical (600351) has declined significantly in Q3 2025, primarily due to the termination of the SY009 research project and the provision for asset impairment [1] Financial Performance Summary - Q3 2025 revenue reached 569 million yuan, a year-on-year decrease of 16.01% [1] - Q3 2025 net profit was 40.6971 million yuan, down 26.22% year-on-year [1] - Revenue for the first three quarters totaled 1.709 billion yuan, reflecting a 19.46% year-on-year decline [1] - Net profit for the first three quarters was 215 million yuan, a decrease of 8.44% year-on-year [1] - Basic earnings per share stood at 0.3066 yuan [1]